Rexford Capital’s Pfizer PFE Stock Holding History

Rexford Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$420K	Sell	17,445 -133	-0.8%	-$3.48K	0.26%	108
2026 Q1	$494K	Buy	17,578 +149	+0.9%	+$3.97K	0.35%	83
2025 Q4	$434K	Sell	17,429 -1,520	-8%	-$38.3K	0.33%	94
2025 Q3	$483K	Buy	18,949 +300	+2%	+$7.41K	0.37%	86
2025 Q2	$452K	Buy	+18,649	New	+$435K	0.38%	84

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Rexford Capital's PFE Position: Q2 2026 in Review

Rexford Capital reduced its Pfizer (PFE) stake by 0.76% in Q2 2026, selling an estimated $3.48K and leaving 17,445 shares worth $420K. The position accounts for 0.26% of the portfolio, ranked #108.

Rexford Capital first reported a position in PFE in Q2 2025 and has held it in 5 quarters since. The position peaked at $494K in Q1 2026. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Rexford Capital held 17,445 shares of Pfizer worth $420K as of Q2 2026.
Rexford Capital sold 133 Pfizer shares in Q2 2026, an estimated $3.48K.
Pfizer made up 0.26% of Rexford Capital's portfolio in Q2 2026, its #108 holding.
Rexford Capital first reported a position in Pfizer in Q2 2025 and has held it in 5 quarters since.
Rexford Capital's Pfizer position peaked at $494K in Q1 2026.
2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Rexford Capital's 13F filing for Q2 2026, filed 29 Jul 2026.